Clinical trials
Phase 1 Mesothelioma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
90 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 6 |
| 2007 | 7 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 9 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 9 |
| 2020 | 8 |
| 2021 | 6 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Terminated | 23 |
| Recruiting | 8 |
| Active, not recruiting | 7 |
| Unknown status | 5 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 9 |
| Incyte Corporation | 4 |
| Erasmus Medical Center | 3 |
| Novartis Pharmaceuticals | 3 |
| AbbVie | 2 |
| Bayer | 2 |
| M.D. Anderson Cancer Center | 2 |
| Morphotek | 2 |
| NGM Biopharmaceuticals, Inc | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mesothelioma | 90 |
| Carcinoma, Non-Small-Cell Lung | 37 |
| Ovarian Neoplasms | 27 |
| Melanoma | 24 |
| Colorectal Neoplasms | 19 |
| Stomach Neoplasms | 19 |
| Carcinoma, Renal Cell | 18 |
| Lung Neoplasms | 18 |
| Pancreatic Neoplasms | 16 |
| Uterine Cervical Neoplasms | 16 |
Trials
Showing 51 to 75 of 90. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.